We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ikena Oncology Inc | NASDAQ:IKNA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.31 | 1.31 | 1.33 | 1.35 | 1.29 | 1.34 | 235,735 | 22:05:48 |
Ikena CEO Mark Manfredi, Ph.D., will present a corporate update at the H.C. Wainwright Global Investment Conference and management will attend virtually. They will also participate in a fireside chat at the Jefferies Global Healthcare Conference and will attend the conference live in New York City.
Details can be found below:
H.C Wainwright Global Investment Conference |
Corporate Presentation |
Date: May 25, 2022, 11:30 a.m. ET |
Webcast Link |
Jefferies Global Healthcare Conference |
Fireside Chat |
Date: June 9, 2022, 10:00 a.m. ET |
Webcast Link |
The presentation webcasts will be available on the Company’s Events & Presentations page on their website at www.ikenaoncology.com.
About Ikena OncologyIkena OncologyTM is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer. The Company’s lead targeted oncology program, IK-930, is a TEAD inhibitor addressing the Hippo signaling pathway, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company’s ongoing discovery research spans other targets in the Hippo pathway as well as the RAS signaling pathway. Additional programs targeting the tumor microenvironment and immune signaling are in the clinic, including IK-175, an aryl hydrocarbon receptor antagonist, which is being developed in collaboration with Bristol Myers Squibb. Ikena’s pipeline is built on addressing genetically defined or biomarker-driven cancers and developing therapies that can serve specific patient populations in need of new therapeutic options. To learn more, visit www.ikenaoncology.com or follow us on Twitter and LinkedIn.
Investor Contact:Rebecca CohenIkena Oncologyrcohen@ikenaoncology.com
Media Contact:Gwen SchankerLifeSci Communicationsgschanker@lifescicomms.com
1 Year Ikena Oncology Chart |
1 Month Ikena Oncology Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions